Marcin Zychma
Novo Nordisk (Switzerland)(CH)
Publications by Year
Research Areas
Renin-Angiotensin System Studies, Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Diabetes Management and Research, Pancreatic function and diabetes
Most-Cited Works
- → Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)(2009)1,482 cited
- → Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets(2012)158 cited
- → Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16‐week, randomized, double‐blind, active control trial *(2010)90 cited
- → Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: Risk of chronic renal failure(2000)52 cited
- → The role of aldose reductase gene in the susceptibility to diabetic nephropathy in Type II (non-insulin-dependent) diabetes mellitus (Short Communication)(1999)50 cited
- → Angiotensin I-converting enzyme gene polymorphisms(1998)42 cited
- → Polymorphisms in the Genes Encoding for Human Kinin Receptors and the Risk of End-Stage Renal Failure(1999)37 cited
- → Role of GLUT1 gene in susceptibility to diabetic nephropathy in type 2 diabetes(2001)34 cited
- → Patient‐reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open‐label study(2011)31 cited
- → The C825T polymorphism in the human G-protein β3 subunit gene is not associated with diabetic nephropathy in Type I diabetes mellitus(1998)25 cited